Insider buying last 90 days
No open-market insider purchases were filed for ESTA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ESTA insider filing, plotted on the chart in Gekko.Open ESTA in Gekko
NASDAQ: ESTA
Establishment Labs (ESTA) Stock Analysis & Forecast
Oct 12 close
$61.63−0.04 (−0.1%)
Gekko Brief
AI summaryOct 12 closeEstablishment Labs drew attention this week on regulatory and analyst news. The FDA cleared 28 additional Motiva implant sizes, expanding the U.S. portfolio down to 105 cc across Mini, Demi, and Full profiles, yet the stock fell 4.26% to EUR 54.60 at Lang & Schwarz following the announcement. Separately, BTIG and Needham issued bullish ratings on the name, and earlier coverage noted Q2 2026 results with total revenue of $67.5 million, up 31.7% year-over-year, driven by a 140.9% surge in U.S. revenue.
The stock closes at $61.63, down 0.1%, sitting below both its 50-day average of $71.77 and its 200-day average of $72.92, with the 50-day below the 200-day. Three-month performance stands at -28.8% while the one-year return remains positive at 53.6%. The GekkoIndex reads 68.8, placing the stock in the Accumulation zone, and price sits 26.7% below the Gekko Fair Value of $84.09.
Earnings are scheduled for 4 November 2026, before the open, 22 days out and inside a typical 20-trading-day holding window; the last report showed an EPS miss of -0.39 versus -0.34 estimated, with a -15.2% reaction, against a history of 4 beats in 8 quarters and an average absolute reaction of 12.3%. Seasonality from this point in the calendar has averaged +14.6% over the next 20 trading days across 5 years, rising in 3 of them. No insider, Congress, or unusual options activity appears in the respective windows, and consensus among 8 analysts stands at buy with a target of $102.44.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Establishment Labs price vs fair value
Close $61.63200-day averageGekko Fair Value $84.09
Establishment Labs quick facts
- Market cap
- $1.81B
- P/E ratio
- —
- Forward P/E
- 204.1
- EPS, TTM
- −$1.30
- Revenue, TTM
- $245.8M
- Profit margin
- -15.8%
- Dividend yield
- —
- Beta
- 1.06
- Volume
- 277,896 avg 339,921
- 1-year return
- +53.6%
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±9.9%
- 50-day average
- $71.77
- 200-day average
- $72.92
- Next earnings
- Nov 4 before open
- Shares outstanding
- 29.80M
Establishment Labs swing-trade checklist
Establishment Labs scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $61.63 is below the 50-day ($71.77) and 200-day ($72.92) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
68.8, Accumulation
Reading 68.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
26.7% below
Price is 26.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+14.6% on average
From this point in the calendar, the next 20 trading days averaged +14.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Establishment Labs stock chart and price history
Establishment Labs closed at $61.63 on Oct 12, 2026, +53.6% over the past year, inside a 52-week range of $38.38 to $97.59.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.1%
- 3 months
- −28.8%
- 6 months
- −2.1%
- 1 year
- +53.6%
The full ESTA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ESTA in Gekko
Follow Establishment Labs through every session
Put ESTA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ESTA in GekkoFree for 7 days. No credit card required.
About Establishment Labs
Establishment Labs designs and sells medical devices used in aesthetic and reconstructive plastic surgery. Its best known products are silicone gel-filled breast implants marketed under the Motiva Implants name, including the Motiva Ergonomix and Motiva Ergonomix2 lines, which are round, soft gel-filled implants that respond to gravity. The company also makes the Motiva Flora Tissue Expander for breast tissue and offers the Puregraft line, used to collect and reposition a patient's own fat tissue.
The company reaches surgeons and medical customers through a combination of its own direct sales staff and exclusive outside distributors. Its products are sold across Europe, Latin America, the Asia-Pacific region, and other markets worldwide, rather than being limited to a single geography.
Establishment Labs was founded in 2004 and is headquartered in Alajuela, Costa Rica. Its shares are listed on the NASDAQ under the ticker ESTA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- establishmentlabs.com
Establishment Labs GekkoIndex: the smart money zone
Establishment Labs’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.8, in the Accumulation zone, up 3.5 points over five sessions.
68.8Accumulation
Up 3.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 44 | +5.1% | +7.0% | ||
| Accumulation (current zone) | 175 | +1.3% | +5.7% | ||
| Neutral | 411 | +0.2% | +0.6% | ||
| Distribution | 48 | +0.2% | +11.6% | ||
| Selling | 4 | Too few readings yet | |||
Average ESTA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ESTA price, zone by zone.Track ESTA in Gekko
Is Establishment Labs stock overvalued? Gekko Fair Value
Establishment Labs trades 26.7% below Gekko Fair Value of $84.09, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Establishment Labs shares are worth, recalculated every trading day.
$84.09
Gekko Fair Value, Oct 10, 2026
26.7% Undervalued
At the end of Aug 2026 the price was 27.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ESTA in Gekko
Establishment Labs insider and Congress trading
No open-market insider purchases were filed for Establishment Labs, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ESTA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ESTA, plotted on the chart in Gekko.Open ESTA in Gekko
Buybacks
Establishment Labs has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2024
- $119K
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ESTA.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Establishment Labs earnings: next date and track record
Establishment Labs reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- −$0.26
- Revenue estimate
- $66.79M
4 of 8reports beat the EPS estimate
±12.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.39 est −$0.34 | $67.54M est $65.79M | −15.2% |
| May 6, 2026 | −$0.40 est −$0.38 | $59.88M est $57.40M | +1.5% |
| Feb 24, 2026 | −$0.09 est −$0.22 | $64.62M est $63.80M | +4.4% |
| Nov 5, 2025 | −$0.38 est −$0.54 | $53.78M est $63.80M | +31.4% |
| Aug 7, 2025 | −$0.57 est −$0.54 | $51.30M est $52.48M | −16.7% |
| May 7, 2025 | −$0.70 est −$0.83 | $41.38M est $41.11M | +5.4% |
| Feb 26, 2025 | −$1.19 est −$0.66 | $44.51M est $44.45M | +18.9% |
| Nov 7, 2024 | −$0.59 est −$0.61 | $40.23M est $44.69M | −5.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Establishment Labs stock forecast and analyst price targets
Analysts’ average 12-month price target for Establishment Labs is $102.44, +66.2% from the last close, from 8 firms rating the stock in the last 90 days.
$102.44consensus 12-month target, +66.2% from the last close
Now $61.63Avg $102.44
Low $92High $117
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | Canaccord Genuity | $105 | +70.4% |
| Oct 5 | TD Cowen | $117 | +89.8% |
| Oct 5 | BTIG | $103 | +67.1% |
| Sep 24 | TD Cowen | $117 | +89.8% |
| Sep 8 | Jefferies | $105 | +70.4% |
+5.7%average 20-day move after past Accumulation readings
+14.6%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Establishment Labs seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Establishment Labs averaged +14.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +7.4% | 4 of 5 |
| Next 10 trading days | +4.9% | 3 of 5 |
| Next 15 trading days | +4.5% | 4 of 5 |
| Next 20 trading days | +14.6% | 3 of 5 |
| Next 30 trading days | +8.0% | 3 of 5 |
For scale, ESTA’s typical 20-trading-day move in either direction is about 9.9%.
Establishment Labs market cap and key statistics
Establishment Labs’s market cap is $1.81B and revenue of $245.8M over the last twelve months.
Valuation
- Market cap
- $1.81B
- Forward P/E
- 204.1
- EPS, TTM
- −$1.30
- Gekko Fair Value
- $84.09
Trading
- Volume
- 277,896
- Avg volume, 20 days
- 339,921
- 52-week high
- $97.59
- 52-week low
- $38.38
- Shares outstanding
- 29.80M
Financials
- Revenue, TTM
- $245.8M
- Profit margin
- -15.8%
- Return on equity
- -175.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.06
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±9.9%
Establishment Labs stock news this week
Coverage of Establishment Labs this week reads neutral: 2 positive, 1 neutral and 2 negative headlines.
- Why (ESTA) Price Action Is Critical for Tactical TradingStock Traders Daily, Oct 11
- Establishment Labs clears 28 implant sizes. Establishment Labs stock falls 4.26 percentAD HOC NEWS, Oct 8
- Establishment Labs Holdings Inc. (ESTA) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Oct 7
- Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Establishment Labs Holdings (ESTA)The Globe and Mail, Oct 7
- Contrasting Establishment Labs (NASDAQ:ESTA) & OraSure Technologies (NASDAQ:OSUR)Defense World, Oct 7
- Establishment Labs Hldgs Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga, Oct 6
Establishment Labs peers
Establishment Labs’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Establishment Labs stock FAQ
What is Establishment Labs’s market cap?
Establishment Labs’s market cap is $1.81B at the Oct 12, 2026 close of $61.63, with 29.80M shares outstanding.
What is the Establishment Labs stock forecast?
The consensus analyst 12-month price target for Establishment Labs is $102.44, +66.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Establishment Labs stock overvalued or undervalued?
On Gekko’s estimate Establishment Labs is undervalued: the Oct 12, 2026 close of $61.63 is 26.7% below Gekko Fair Value of $84.09. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Establishment Labs report earnings next?
Establishment Labs is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of −$0.26 per share on revenue of $66.79M. Establishment Labs beat the earnings estimate in 4 of its last 8 reports, moving 12.3% on average across the report.
What is Establishment Labs’s 52-week high and low?
Establishment Labs’s 52-week high is $97.59 and its 52-week low is $38.38; it closed at $61.63 on Oct 12, 2026, +53.6% over the past year.
Is Establishment Labs stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Establishment Labs the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.